Zydus granted Orphan Drug Designation by the USFDA for Saroglitazar in the treatment of patients with Primary Biliary Cholangitis (PBC)

Zydus granted Orphan Drug Designation by the USFDA for Saroglitazar in the treatment of patients with Primary Biliary Cholangitis (PBC) admin Thu, 01/28/2021 - 16:23

source https://www.pharmatutor.org/pharma-news/2021/zydus-granted-orphan-drug-designation-by-the-usfda-for-saroglitazar-in-the-treatment-of-patients-with-primary-biliary-cholangitis